-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 TW7KifGpkbeerXTlsnaF6oEO/24JFPfxDZC83I0/1qCj0TjyB/k0aHCBtceNdpAg
 letvd5XQL82AkrE0cIoopA==

<SEC-DOCUMENT>0000078003-03-000029.txt : 20030428
<SEC-HEADER>0000078003-03-000029.hdr.sgml : 20030428
<ACCEPTANCE-DATETIME>20030428155115
ACCESSION NUMBER:		0000078003-03-000029
CONFORMED SUBMISSION TYPE:	8-K/A
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20030428
ITEM INFORMATION:		Changes in registrant's certifying accountant
FILED AS OF DATE:		20030428

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PFIZER INC
		CENTRAL INDEX KEY:			0000078003
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				135315170
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-03619
		FILM NUMBER:		03666858

	BUSINESS ADDRESS:	
		STREET 1:		235 E 42ND ST
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017
		BUSINESS PHONE:		2125732323

	MAIL ADDRESS:	
		STREET 1:		235 E 42ND ST
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PFIZER CHARLES & CO INC
		DATE OF NAME CHANGE:	19710908
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K/A
<SEQUENCE>1
<FILENAME>k8_a-403.txt
<TEXT>

                      SECURITIES AND EXCHANGE COMMISSION

                          Washington, D.C.  20549


                                  FORM 8-K/A


                               CURRENT REPORT

                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

                         Date of report: April 28, 2003
                Date of earliest event reported: April 16, 2003




                                 PFIZER INC.
           (Exact name of registrant as specified in its charter)

           Delaware                1-3619                13-5315170
      (State or other         (Commission File        (I.R.S. Employer
       jurisdiction of           (Number)           Identification No.)
       incorporation)


            235 East 42nd Street                            10017
            New York, New York                           (Zip Code)
                  (Address of principal executive offices)


              Registrant's telephone number, including area code:
                               (212) 573-2323



Item 4. Changes in Registrant's Certifying Accountants

On April 16, 2003, Pfizer Inc. ("Pfizer") completed its merger with Pharmacia
Corporation ("Pharmacia"). As a result of the merger, Pfizer has engaged KPMG
LLP as its independent auditors to audit the financial statements of the
Pharmacia Savings Plan ("Plan") for the year ended December 31, 2002.  As of
April 16, 2003, PricewaterhouseCoopers LLP ("PWC"), independent auditors of
Pharmacia prior to its acquisition by Pfizer, were dismissed as auditors of
the Plan; the Registrant's Audit Committee was involved in the decision to
change auditors for the Plan. The reports of PWC regarding the Plan's
financial statements as of and for the years ended December 31, 2001 and 2000
did not contain any adverse opinion or disclaimer of opinion or any
qualification or modification as to uncertainty, audit scope or accounting
principles. In connection with its audits for the two most recent fiscal
years and through April 16, 2003, there have been no disagreements with PWC
on any matter of accounting principles or practices, financial statement
disclosure or auditing scope or procedure which, if not resolved to the
satisfaction of PWC, would have caused it to make reference to the matter in
its reports. PWC has been provided with a copy of the foregoing statements.
Attached as Exhibit 16 is a copy of PWC's letter dated April 28, 2003 stating
its agreement with such statements.

The Plan engaged KPMG LLP as its independent accountants to audit the Plan's
financial statements for the year ended December 31, 2002. During the years
ended December 31, 2001 and 2000 and through the filing date of this Current
Report on Form 8-K/A, the Plan did not consult with KPMG LLP on any
accounting or auditing matter.

Item 7(c). Exhibits

(16)       Letter from PricewaterhouseCoopers LLP to the Securities and
           Exchange Commission dated April 28, 2003.



                                   SIGNATURE

Under the requirements of the Securities Exchange Act of 1934, the registrant
has caused this report to be signed on its behalf by the authorized
undersigned.

                            PFIZER INC.


                            By:/s/Margaret M.Foran
                              ____________________________
                               Margaret M. Foran
                               Title: Vice President-Corporate
                               Governance and Secretary



Dated: April 28, 2003


Exhibit No.       Description

   16             Letter from PricewaterhouseCoopers LLP to the Securities
                  and Exchange Commission dated April 28, 2003.

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13
<SEQUENCE>3
<FILENAME>ex16.txt
<TEXT>
                                                     Exhibit 16

April 28, 2003


Securities and Exchange Commission
450 Fifth Street, N. W.
Washington, D. C.  20549

Commissioners:

We have read the statements made by Pfizer Inc. with respect to
the Pharmacia Savings Plan (copy attached), which we understand
will be filed with the Commission, pursuant to Item 4 of Form 8-
K, as part of the Company's Form 8-K/A report dated April 16,
2003. We agree with the statements concerning our Firm in such
Form 8-K/A.

Very truly yours,


PricewaterhouseCoopers LLP


</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
